Clinical trial
A Trial of BMS-512148 in Patients With Type 2 Diabetes Mellitus
NCT00263276 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00263276 |
|---|---|
| Title | A Trial of BMS-512148 in Patients With Type 2 Diabetes Mellitus |
| Official title | A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase 2 Trial to Evaluate the Safety and Efficacy of BMS-512148 as Monotherapy in Subjects With Type 2 Diabetes Mellitus Who Are Treatment Naive And Have Inadequate Glycemic Control on Diet and Exercise |
| Lead sponsor | AstraZeneca, Industry |
| Collaborators | Bristol-Myers Squibb Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Type 2 Diabetes |
| Intervention type | Drug |
| Interventions | dapagliflozin, placebo, metformin |
| Enrollment | 389 |
| Start date | Dec 1, 2005 |
| Primary completion | Feb 1, 2007 |
| Completion | Feb 1, 2007 |
| First posted | Dec 8, 2005 |
| Last update posted | Nov 17, 2016 |
| Countries | Canada, Mexico, Puerto Rico, United States |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: